SupplementaryReferences

References

  • Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, Kaneshima H. HIV induces thymus depletion in vivo. Nature. 1993 Jun 24;363(6431):728-732.
  • Su L, Kaneshima H, Bonyhadi M, Salimi S, Kraft D, Rabin L, McCune JM. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity. 1995 Jan;2(1):25-36.
  • Jamieson BD, Uittenbogaart CH, Schmid I, Zack JA. High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo. Journal of virology. 1997 Nov;71(11):8245-8253.
  • Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C, Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup RA. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol. 2001 Dec 1;167(11):6663-6668.
  • Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med 2001 Nov; 79(11): 631-640.
  • Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, Savona MR, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med Apr; 16(4): 446-451.
  • Samuelsson A, Brostrom C, van Dijk N, Sonnerborg A, Chiodi F. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity. Virology. 1997 Nov 24;238(2):180-188.
  • Nie Z, Bren GD, Rizza SA, Badley AD. HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells. Open Virol J 2008; 2: 1-7.
  • Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995 May 15; 154(10): 5555-5566.
  • Chen JJ, Huang JC, Shirtliff M, Briscoe E, Ali S, Cesani F, Paar D, Cloyd MW. CD4 lymphocytes in the blood of HIV(+) individuals migrate rapidly to lymph nodes and bone marrow: support for homing theory of CD4 cell depletion. J Leukoc Biol. 2002 Aug;72(2):271-278.
  • Ji J, Cloyd MW. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression. Int Immunol. 2009 Mar;21(3):283-294.
  • Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006 Jul 28; 313(5786): 523-526.
  • Paiardini M, Cervasi B, Sumpter B, McClure HM, Sodora DL, Magnani M, Staprans SI, Piedimonte G, Silvestri G. Perturbations of cell cycle control in T cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys. Journal of virology. 2006 Jan;80(2):634-642.
  • Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature. 2009 Jul 23;460(7254):515-519.
  • Hurtrel B, Petit F, Arnoult D, Muller-Trutwin M, Silvestri G, Estaquier J. Apoptosis in SIV infection. Cell Death Differ. 2005 Aug;12 Suppl 1:979-990.
  • Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009 Dec;119(12):3544-3555.
  • Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. The Journal of infectious diseases. 1998 Sep;178(3):669-679.
  • Franceschi C, Franceschini MG, Boschini A, Trenti T, Nuzzo C, Castellani G, et al. Phenotypic characteristics and tendency to apoptosis of peripheral blood mononuclear cells from HIV+ long term non progressors. Cell Death Differ 1997 Dec; 4(8): 815-823.
  • Bahbouhi B, Landay A, Al-Harthi L. Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood. 2004 Jun 15;103(12):4581-4587.
  • Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. The Journal of experimental medicine. 1995 Dec 1;182(6):1759-1767.
  • Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, Goulder P, Klenerman P. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS (London, England). Feb 20;24(4):491-502.
  • El Hed A, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, Valentine F, Littman DR, Unutmaz D. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. The Journal of infectious diseases. Mar 15;201(6):843-854.
  • Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. The Journal of experimental medicine. 1995 Jun 1;181(6):2029-2036.
  • McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry. 1995 Jun 15;22(2):111-114.
  • Aries SP, Schaaf B, Muller C, Dennin RH, Dalhoff K. Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression. J Mol Med. 1995 Dec;73(12):591-593.
  • Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS (London, England). 1996 Jan;10(1):9-16.
  • Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP. Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Blood. 1997 Feb 15;89(4):1357-1363.
  • Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, Bekesi JG. Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin Immunol 1997 Mar; 17(2): 185-192.
  • Dockrell DH, Badley AD, Villacian JS, Heppelmann CJ, Algeciras A, Ziesmer S, Yagita H, Lynch DH, Roche PC, Leibson PJ, Paya CV. The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest. 1998 Jun 1;101(11):2394-2405.
  • Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci U S A 1990 Dec; 87(24): 9620-9624.
  • Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997 Jan 6; 185(1): 55-64.
  • Medrano FJ, Leal M, Arienti D, Rey C, Zagliani A, Torres Y, Sanchez-Quijano A, Lissen E, Clerici M. Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients. AIDS research and human retroviruses. 1998 Jul 1;14(10):835-843.
  • Moretti S, Marcellini S, Boschini A, Famularo G, Santini G, Alesse E, Steinberg SM, Cifone MG, Kroemer G, De Simone C. Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. Clin Exp Immunol. 2000 Dec;122(3):364-373.
  • Wong GH, Krowka JF, Stites DP, Goeddel DV. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma. J Immunol. 1988 Jan 1;140(1):120-124.
  • Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding PA. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex. Biotechnol Ther. 1989;1(3):229-236.
  • Cummins N, Badley A. The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly. Curr Mol Med 2009 Jun; 9(4): 495-505.
  • Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 2005 Nov 15; 106(10): 3524-3531.
  • Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood 2009 Oct 29; 114(18): 3854-3863.
  • Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 2009 Jan;4(1):34-41.
  • Cadogan M, Dalgleish AG. Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med. 2008 Jun;8(3):267-271.
  • Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008 Apr;66(1):52-64.
  • Holm GH, Gabuzda D. Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. Journal of virology. 2005 May;79(10):6299-6311.
  • Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS (London, England). 2008 Oct 1;22(15):2035-2038.
  • Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009 Apr 15; 199(8): 1177-1185.
  • Andrieu JM, Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med. 2004 May 5;2:17.
  • Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. Journal of acquired immune deficiency syndromes. 2002 Apr 1;29(4):356-362.
  • Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, Wang H, Sevin A, Tebas P, Sieg SF, Medvik K, Margolis DM, Pollard R, Ertl HC, Valdez H. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. The Journal of infectious diseases. 2006 Dec 15;194(12):1677-1685.
  • Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Froland SS, Tasken K. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS (London, England). 2006 Apr 4;20(6):813-820.
  • Kaur R, Bedimo R, Kvanli MB, Turner D, Shaw L, Margolis D. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res Ther. 2006;3:16.
  • Engchanil C, Kosalaraksa P, Lumbiganon P, Lulitanond V, Pongjunyakul P, Thuennadee R, Tungsawad S, Suwan-apichon O. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children. J Med Assoc Thai. 2006 Aug;89(8):1229-1236.
  • Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. The Journal of experimental medicine. 1992 Oct 1;176(4):1099-1106.
  • Schwartz O, Alizon M, Heard JM, Danos O. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein. Virology. 1994 Jan;198(1):360-365.
  • Laurent-Crawford AG, Krust B, Riviere Y, Desgranges C, Muller S, Kieny MP, Dauguet C, Hovanessian AG. Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS research and human retroviruses. 1993 Aug;9(8):761-773.
  • Amendola A, Lombardi G, Oliverio S, Colizzi V, Piacentini M. HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by 'tissue' transglutaminase expression and prevented by cyclosporin A. FEBS Lett. 1994 Feb 21;339(3):258-264.
  • Laurent-Crawford AG, Coccia E, Krust B, Hovanessian AG. Membrane-expressed HIV envelope glycoprotein heterodimer is a powerful inducer of cell death in uninfected CD4+ target cells. Res Virol. 1995 Jan-Feb;146(1):5-17.
  • Foster S, Beverley P, Aspinall R. gp120-induced programmed cell death in recently activated T cells without subsequent ligation of the T cell receptor. Eur J Immunol. 1995 Jun;25(6):1778-1782.
  • Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 2003 May; 77(10): 5846-5854.
  • Perfettini JL, Castedo M, Roumier T, Andreau K, Nardacci R, Piacentini M, et al. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ 2005 Aug; 12 Suppl 1: 916-923.
  • Uchiyama J, Kishi S, Yagita H, Matsuzaki S, Koga Y. Fas ligand-mediated depletion of CD4 and CD8 lymphocytes by monomeric HIV-1-gp120. Arch Virol. 1997;142(9):1771-1785.
  • Muller WE, Pergande G, Ushijima H, Schleger C, Kelve M, Perovic S. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog Mol Subcell Biol. 1996;16:44-57.
  • Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS research and human retroviruses. 1999 Sep 20;15(14):1265-1277.
  • Twu C, Liu NQ, Popik W, Bukrinsky M, Sayre J, Roberts J, Rania S, Bramhandam V, Roos KP, MacLellan WR, Fiala M. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14386-14391.
  • Kapasi AA, Patel G, Franki N, Singhal PC. HIV-1 gp120-induced tubular epithelial cell apoptosis is mediated through p38-MAPK phosphorylation. Mol Med. 2002 Nov;8(11):676-685.
  • Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. The Journal of infectious diseases. 2003 Oct 15;188(8):1192-1204.
  • Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. The Journal of infectious diseases. 2003 Nov 15;188(10):1455-1460.
  • Acheampong EA, Parveen Z, Muthoga LW, Wasmuth-Peroud V, Kalayeh M, Bashir A, Diecidue R, Mukhtar M, Pomerantz RJ. Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes. Journal of virology. 2005 Jul;79(13):8440-8453.
  • Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005 Aug 12;333(4):1107-1115.
  • Endo M, Inatsu A, Hashimoto K, Takamune N, Shoji S, Misumi S. Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4. Curr HIV Res. 2008 Jan;6(1):34-42.
  • Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, Giardino R, Re MC. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol. 2008 Sep;80(9):1507-1514.
  • Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW, Jr. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther. 2009 Jan;8(1):178-184.
  • Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS (London, England). 1997 Oct;11(12):1421-1431.
  • Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, Herzenberg LA, Herzenberg LA. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5111-5116.
  • Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, et al. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 1995 Nov 15; 86(10): 3823-3834.
  • Zhang M, Li X, Pang X, Ding L, Wood O, Clouse K, Hewlett I, Dayton AI. Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J Biomed Sci. 2001 May-Jun;8(3):290-296.
  • Collins KL. This bud's for Vpu. Cell Host Microbe. 2009 Mar 19;5(3):217-219.
  • Joseph AM, Kumar M, Mitra D. Nef: "necessary and enforcing factor" in HIV infection. Curr HIV Res. 2005 Jan;3(1):87-94.
  • Okada H, Takei R, Tashiro M. HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). FEBS Lett. 1997 Sep 15;414(3):603-606.
  • Xu XN, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, Mongkolsapay J, McMichael AJ, Baur AS. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. The Journal of experimental medicine. 1999 May 3;189(9):1489-1496.
  • Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol. 2008 Aug;85(1):2-10.
  • Chang LJ, Chen CH, Urlacher V, Lee TZ. Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells. J Biomed Sci. 2000 Jul-Aug;7(4):322-333.
  • Conti L, Matarrese P, Varano B, Gauzzi MC, Sato A, Malorni W, Belardelli F, Gessani S. Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J Immunol. 2000 Sep 15;165(6):3293-3300.
  • Jian H, Zhao LJ. Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is subtype-dependent and potently enhanced by nonconservative changes of the leucine residue at position 64. J Biol Chem 2003 Nov 7; 278(45): 44326-44330.
  • Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, Jacquot G, et al. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog 2006 Dec; 2(12): e127.
  • Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res. 1999 Aug 25;251(1):156-165.
  • Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, Weiner DB. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem. 2002 Oct 4;277(40):37820-37831.
  • Arunagiri C, Macreadie I, Hewish D, Azad A. A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis. 1997;2(1):69-76.
  • Yasuda J, Miyao T, Kamata M, Aida Y, Iwakura Y. T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene. Virology 2001 Jul 5; 285(2): 181-192.
  • Muthumani K, Lambert VM, Sardesai NY, Kim JJ, Heller R, Weiner DB, et al. Analysis of the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res 2009 Mar; 7(2): 144-152.
  • Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, et al. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 2002 Nov; 9(11): 1172-1184.
  • Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, Ecto LT, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. Journal of acquired immune deficiency syndromes. 1993 Jul;6(7):787-794.
  • Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB, Bell N, Limjuco RA, Guthrie KI, et al. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. International journal of clinical pharmacology, therapy, and toxicology. 1993 Jul;31(7):343-350.
  • Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L, et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. The Journal of infectious diseases. 1995 Jun;171(6):1628-1632.
  • Kruse A, Rieneck K, Kappel M, Orholm M, Bruunsgaard H, Ullum H, Skinhoj P, Pedersen BK. Pentoxifylline therapy in HIV seropositive subjects with elevated TNF. Immunopharmacology. 1995 Nov;31(1):85-91.
  • Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, Ruzzante S, Longhi R, Colombo MC, Moroni M, Milazzo F.